CELU celularity.com: מקדם חוב לטווח ארוך להון

The long-term debt-to-equity chart in the GURU.Markets system is available for analyzing the liability structure of Celularity Inc. (CELU), where 0.00 captures the current state of the parameter. Celularity Inc. relies on external contractors to conduct tests while maintaining internal production control. Stable demand for biotechnology makes the asset a defensive asset against recessions. Its status as an innovator in cell therapy confirms the brand's high authority.

The fundamental risk of Celularity Inc. (CELU) is assessed through the resilience of its balance sheet structure to external shocks. High expenditures on external contractors during clinical trials necessitate strict control over long-term financing. This long-term debt-to-equity ratio compares loans with maturities exceeding one year against the issuer's own funds. The metric allows for the differentiation of scheduled debt service from new equity issuances. While low values minimize the probability of default, a complete absence of leverage may limit the company's expansion.